Genetic polymorphisms of CYP2C9, CYP2C19, and CYP3A5 in Kosovar population

Open access

Abstract

Cytochrome P450 genetic polymorphisms are responsible for individual variations in drug metabolism and drug-drug interactions. They are very important for pharmacogenetics, and their frequency varies across different populations. There is a big gap in the knowledge about the CYP gene family polymorphisms in the population of Kosovo, and the aim of our study was to fill that gap by determining the frequency of the most important variant alleles of CYP2C9, CYP2C19, and CYP3A5 in 234 nonrelated Kosovars. The allele frequencies of CYP2C9*2 and 2C9*3 were 17.52 %, and 10.89 %, respectively. Sixteen participants (6.81 %) were CYP2C9 poor metabolisers. The CYP2C19*2 and *17 variant frequencies were 13.03 % and 19.01 %, respectively. There were 2.13 % CYP2C19 poor and 4.27 % ultra-rapid metabolisers (homozygous carriers of the *17 allele). With regard to CYP3A5, the frequency of the *3 variant allele was 98.29 % (non-expressors), while the remaining participants (1.70 %) were expressors of CYP3A5. These findings are comparable with other European ethnicities, specifically those of Southeast Europe.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • 1. Lam TN Hunt CA. Mechanistic insight from in silico pharmacokinetic experiments: roles of P-glycoprotein Cyp3A4 enzymes and microenvironments. J Pharmacol Exp Ther 2010;332:398-412. doi:

    • Crossref
    • Export Citation
  • 2. Preissner SC Hoffmann MF Preissner R Dunkel M Gewiess A Preissner S. Polymorphic cytochrome P450 enzymes (CYPs) and their role in personalized therapy. PloS One 2013;8(12):e82562. doi:

    • Crossref
    • Export Citation
  • 3. Kantae V Krekels EH Esdonk MJ Lindenburg P Harms AC Knibbe CA Van der Graaf PH Hankemeier T. Integration of pharmacometabolomics with pharmacokinetics and pharmacodynamics: towards personalized drug therapy. Metabolomics 2017;13:9. doi:

    • Crossref
    • Export Citation
  • 4. Phillips KA Veenstra DL Oren E Lee JK Sadee W. Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. JAMA. 2001;286:2270-9. doi:

    • Crossref
    • Export Citation
  • 5. Hiratsuka M. In vitro assessment of the allelic variants of cytochrome P450. Drug Metab Pharmacokinet 2012;27:68-84. doi:

    • Crossref
    • Export Citation
  • 6. Krasniqi V Dimovski A Domjanović IK Bilic I Božina N. How polymorphisms of the cytochrome P450 genes affect ibuprofen and diclofenac metabolism and toxicity. Arh Hig Rada Toksikol. 2016;67:1-8. doi:

    • Crossref
    • Export Citation
  • 7. Beitelshees AL Voora D Lewis JP. Personalized antiplatelet and anticoagulation therapy: applications and significance of pharmacogenomics. Pharmgenomics Pers Med 2015;8:43-61. doi:

    • Crossref
    • Export Citation
  • 8. Schuck RN Grillo JA. Pharmacogenomic biomarkers: an FDA perspective on utilization in biological product labeling. AAPS J 2016;18:573-7. doi:

    • Crossref
    • Export Citation
  • 9. Gaikovitch EA Cascorbi I Mrozikiewicz PM Brockmoller J Frotschl R Kopke K Gerloff T Chernov JN Roots I. Polymorphisms of drug-metabolizing enzymes CYP2C9 CYP2C19 CYP2D6 CYP1A1 NAT2 and of P-glycoprotein in a Russian population. Eur J Clin Pharmacol 2003;59:303-12.doi:

    • Crossref
    • Export Citation
  • 10. Scordo MG Caputi AP D’Arrigo C Fava G Spina E. Allele and genotype frequencies of CYP2C9 CYP2C19 and CYP2D6 in an Italian population. Pharmacol Res 2004;50:195-200. doi:

    • Crossref
    • Export Citation
  • 11. Scott SA Sangkuhl K Shuldiner AR Hulot JS Thorn CF Altman RB Klein TE. PharmGKB summary: very important pharmacogene information for cytochrome P450 family 2 subfamily C polypeptide 19. Pharmacogenet Genomics 2012;22:159-65. doi:

    • Crossref
    • Export Citation
  • 12. Lamba J Hebert JM Schuetz EG Klein TE Altman RB. PharmGKB summary: very important pharmacogene information for CYP3A5. Pharmacogenet Genomics 2012;22:555-8. doi:

    • Crossref
    • Export Citation
  • 13. Arici M Özhan G. CYP2C9 CYPC19 and CYP2D6 gene profiles and gene susceptibility to drug response and toxicity in Turkish population. Saudi Pharm J 2017;25:376-80. doi:

    • Crossref
    • Export Citation
  • 14. Božina N Granić P Lalić Z Tramišak I Lovrić M Stavljenić- Rukavina A. Genetic polymorphisms of cytochromes P450: CYP2C9 CYP2C19 and CYP2D6 in Croatian population. Croat Med J 2003;44:425-8. PMID: 12950145

  • 15. Yang JQ Morin S Verstuyft C Fan LA Zhang Y Xu CD Barbu V Funck-Brentano C Jaillon P Becquemont L. Frequency of cytochrome P450 2C9 allelic variants in the Chinese and French populations. Fundam Clin Pharmacol 2003;17:373-6. doi:

    • Crossref
    • Export Citation
  • 16. IGSR: The International Genome Sample Resource. Providing ongoing support for the 1000 Genomes Project data [displayed 30 August 2017]. Available at http://www.internationalgenome.org

  • 17. Jakovski K Nestorovska AK Labacevski N Dimovski AJ. Characterization of the most common CYP2C9 and CYP2C19 allelic variants in the population from the Republic of Macedonia. Pharmazie 2013;68:893-8. doi:

    • Crossref
    • Export Citation
  • 18. Daly AK. Pharmacogenetics of drug metabolizing enzymes in the United Kingdom population: review of current knowledge and comparison with selected European populations. Drug Metab Pers Ther 2015;30:165-74. doi:

    • Crossref
    • Export Citation
  • 19. Buzoianu AD Trifa AP Muresanu DF Crisan S. Analysis of CYP2C9*2 CYP2C9*3 and VKORC1 -1639 G>A polymorphisms in a population from South-Eastern Europe. J CellMolMed2 0 1 2 ; 1 6 : 2 9 1 9 - 2 4 . d o i : 10.1111/j.1582-4934.2012.01606.x

  • 20. Yasar U Eliasson E Dahl ML Johansson I Ingelman- Sundberg M Sjöqvist F. Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population. Biochem Biophys Res Commun 1999;254:628-31. doi:

    • Crossref
    • Export Citation
  • 21. Burian M Grösch S Tegeder I Geisslinger G. Validation of a new fluorogenic real-time PCR assay for detection of CYP2C9 allelic variants and CYP2C9 allelic distribution in a German population. Br J Clin Pharmacol 2002;54:518-21. doi:

    • Crossref
    • Export Citation
  • 22. Dorado P Berecz R Norberto MJ Yasar U Dahl ML A LL. CYP2C9 genotypes and diclofenac metabolism in Spanish healthy volunteers. Eur J Clin Pharmacol 2003;59:221-5. doi:

    • Crossref
    • Export Citation
  • 23. Arvanitidis K Ragia G Iordanidou M Kyriaki S Xanthi A Tavridou A Manolopoulos VG. Genetic polymorphisms of drug-metabolizing enzymes CYP2D6 CYP2C9 CYP2C19 and CYP3A5 in the Greek population. Fundam Clin Pharmacol 2007;21:419-26. doi:

    • Crossref
    • Export Citation
  • 24. Ganoci L Božina T Mirošević Skvrce N Lovrić M Mas P Božina N. Genetic polymorphisms of cytochrome P450 enzymes: CYP2C9 CYP2C19 CYP2D6 CYP3A4 and CYP3A5 in the Croatian population. Drug Metab Pers Ther 2017;32:11-21. doi:

    • Crossref
    • Export Citation
  • 25. Chaudhary N Kabra M Gulati S Gupta YK Pandey RM Bhatia BD. Frequencies of CYP2C9 polymorphisms in North Indian population and their association with drug levels in children on phenytoin monotherapy. BMC Pediatr 2016;16:66. doi:

    • Crossref
    • Export Citation
  • 26. Allabi AC Gala JL Desager JP Heusterspreute M Horsmans Y. Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations. Br J Clin Pharmacol 2003;56:653-7. doi:

    • Crossref
    • Export Citation
  • 27. Sipeky C Lakner L Szabo M Takacs I Tamasi V Polgar N Falus A Melegh B. Interethnic differences of CYP2C9 alleles in healthy Hungarian and Roma population samples: relationship to worldwide allelic frequencies. Blood Cells Mol Dis 2009;43:239-42. doi:

    • Crossref
    • Export Citation
  • 28. Kapedanovska Nestorovska A Jakovski K Naumovska Z Hiljadnikova Bajro M Sterjev Z Eftimov A Matevska Geskovska N Suturkova L Dimitrovski K Labacevski N Dimovski AJ. Distribution of the most common genetic variants associated with a variable drug response in the population of the Republic of Macedonia. Balkan J Med Genet 2015;17:5-14. doi:

    • Crossref
    • Export Citation
  • 29. Payan M Tajik N Rouini MR Ghahremani MH. Genotype and allele frequency of CYP2C19*17 in a healthy Iranian population. Med J Islam Repub Iran 2015;29:269. PMCID: PMC4715407

  • 30. Scott SA Sangkuhl K Gardner EE Stein CM Hulot JS Johnson JA Roden DM Klein TE Shuldiner AR; Clinical Pharmacogenetics Implementation Consortium. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Clin Pharmacol Ther 2011;90:328-32. doi:

    • Crossref
    • Export Citation
  • 31. Ragia G Arvanitidis KI Tavridou A Manolopoulos VG. Need for reassessment of reported CYP2C19 allele frequencies in various populations in view of CYP2C19*17 discovery: the case of Greece. Pharmacogenomics 2009;10:43-9. doi:

    • Crossref
    • Export Citation
  • 32. Fricke-Galindo I Cespedes-Garro C Rodrigues-Soares F Naranjo ME Delgado A de Andres F López-López M Peñas- Lledó E LLerena A1 Interethnic variation of CYP2C19 alleles ‘predicted’ phenotypes and ‘measured’ metabolic phenotypes across world populations. Pharmacogenomics J 2016;16:113-23. doi:

    • Crossref
    • Export Citation
  • 33. Baldwin RM Ohlsson S Pedersen RS Mwinyi J Ingelman- Sundberg M Eliasson E Bertilsson L. Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers. Br J Clin Pharmacol2 0 0 8 ; 6 5 : 7 6 7 - 7 4 . d o i : 10.1111/j.1365-2125.2008.03104.x

  • 34. Frere C Cuisset T Gaborit B Alessi MC Hulot JS. The CYP2C19*17 allele is associated with better platelet response to clopidogrel in patients admitted for non-ST acute coronary syndrome. J Thromb Haemost 2009;7:1409-11. doi:

    • Crossref
    • Export Citation
  • 35. Sibbing D Gebhard D Koch W Braun S Stegherr J Morath T Von Beckerath N Mehilli J Schömig A Schuster T Kastrati A. Isolated and interactive impact of common CYP2C19 genetic variants on the antiplatelet effect of chronic clopidogrel therapy. J Thromb Haemost 2010;8:1685-93. doi:

    • Crossref
    • Export Citation
  • 36. Hicks JK Sangkuhl K Swen JJ Ellingrod VL Muller DJ Shimoda K Bishop JR Kharasch ED Skaar TC Gaedigk A Dunnenberger HM Klein TE Caudle KE Sting JC. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther 2017;102:37-44. doi:

    • Crossref
    • Export Citation
  • 37. Sychev DA Denisenko NP Sizova ZM Grachev AV Velikolug KA. The frequency of CYP2C19 genetic polymorphisms in Russian patients with peptic ulcers treated with proton pump inhibitors. Pharmgenomics Pers Med 2015;8:111-4. doi:

    • Crossref
    • Export Citation
  • 38. Barrera-Pulido L Aguilera-Garcia I Docobo-Perez F Alamo- Martinez JM Pareja-Ciuro F Nunez-Roldan A Gómez-Bravo MA Bernardos-Rodríguez A. Clinical relevance and prevalence of polymorphisms in CYP3A5 and MDR1 genes that encode tacrolimus biotransformation enzymes in liver transplant recipients. Transplant Proc 2008;40:2949-51. doi:

    • Crossref
    • Export Citation
  • 39. Ma LM Liu HC Ruan LH Feng YM. CYP3A5 * 3 genetic polymorphism is associated with childhood acute lymphoblastic leukemia risk: A meta-analysis. Biomed J 2015;38:428-32. doi:

    • Crossref
    • Export Citation
  • 40. Adler G Loniewska B Parczewski M Kordek A Ciechanowicz A. Frequency of common CYP3A5 gene variants in healthy Polish newborn infants. Pharmacol Rep 2009;61:947-51. doi:

    • Crossref
    • Export Citation
Search
Journal information
Impact Factor

IMPACT FACTOR 2018: 1.436
5-year IMPACT FACTOR: 1.606

CiteScore 2018: 1.53

SCImago Journal Rank (SJR) 2018: 0.358
Source Normalized Impact per Paper (SNIP) 2018: 0.608

Cited By
Metrics
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 370 212 16
PDF Downloads 197 114 5